Doctors at a hospital here used a new drug called RLF-100, also known as aviptadil, which led to an immediate recovery from respiratory failure in patients with critically ill COVID-19.
The drug has been approved by the FDA for emergency use at several clinical sites in patients who must also participate in FDA Phase 2/3 trials.
Houston Methodist Hospital was the first to report immediate recovery of respirator patients and those in severe medical situations after 3 days of treatment.
Aviptadil is a vasoactive intestinal polypeptide (VIP) formula, which is provided in maximum concentrations in the lungs and is known to block inflammatory cytokines. NeuroRx and Relief Therapeutics have partnered to expand the drug.
According to a report by drug manufacturer NeuroRX, independent researchers reported that aviptadil blocked replication of SARS coronavirus in human lung cells and monocytes.
According to the report, a 54-year-old man who received COVID-19 while being treated for the rejection of a double lung transplant came out of a fan in four days. Similar effects were observed in more than 15 patients.
The drug appears to have rapidly eliminated the effects of pneumonia on x-rays, increased oxygen in the blood and reduced laboratory markers related to COVID-19 inflammation on average, he said.
“No other antiviral agent has demonstrated a cure for a viral infection and has demonstrated inhibition of viral replication in the lab,” said Professor Jonathan Javitt, ceo and president of NeuroRx.
Essential for coronavirus The Oxford vaccine may be the first for Indians; International air is growing